{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:37:41Z","timestamp":1789544261252,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This retrospective cohort study used an electronic health record\u2010derived, de\u2010identified, US patient\u2010level database to better understand the real\u2010world treatment experience, in a predominantly community setting (80.3% of patients), of venetoclax+hypomethylating agents (HMAs) in routine clinical care, pre\u2010 and post\u2010VIALE\u2010A, to determine whether the post\u2010remission cytopenia management insight from VIALE\u2010A was reflected in real\u2010world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with newly diagnosed acute myeloid leukemia (AML;\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009498), who initiated venetoclax+HMA \u226430\u2009days from AML diagnosis from June 1, 2018, to March 31, 2021, were stratified into pre\u2010(\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009330) and post\u2010(\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009168) VIALE\u2010A cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>More patients in the post\u2010(61%) versus pre\u2010(45%) VIALE\u2010A cohort had their first biopsy by 28\u2009\u00b1\u200914\u2009days post\u2010treatment initiation. Patients underwent bone marrow (BM) assessment earlier in the post\u2010 versus pre\u2010VIALE\u2010A cohort, and first identification of response was also earlier (2.5 vs 5.1\u2009months, respectively). More venetoclax schedule modifications post\u2010remission occurred among post\u2010(82.1%) versus pre\u2010(73.8%) VIALE\u2010A responders; the most common reason for modification was treatment toxicities, specifically cytopenia. Treatment survival outcomes were comparable with or without venetoclax schedule modifications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings suggest that venetoclax schedule modifications can be used to manage cytopenia events without adversely affecting outcomes. Opportunities remain to improve earlier BM assessment to determine venetoclax schedule modifications, providing the best chance for optimal treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.6430","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:57:35Z","timestamp":1691801855000},"page":"17914-17923","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Post\u2010remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre\u2010 versus post\u2010VIALE\u2010A real\u2010world experience from a predominantly US community setting"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-6217","authenticated-orcid":false,"given":"Pankit","family":"Vachhani","sequence":"first","affiliation":[{"name":"O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esprit","family":"Ma","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Montez","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Worth","sequence":"additional","affiliation":[{"name":"O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archibong","family":"Yellow\u2010Duke","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei\u2010Han","family":"Cheng","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Werner","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Abbas","sequence":"additional","affiliation":[{"name":"Tennessee Oncology  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Donnellan","sequence":"additional","affiliation":[{"name":"Tennessee Oncology  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134832"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26692"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac135"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25369"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0612-8"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001239"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151586"},{"key":"e_1_2_13_11_1","doi-asserted-by":"crossref","unstructured":"MaX LongL MoonS AdamsonBJS BaxiSS.Comparison of population characteristics in real\u2010world clinical oncology databases in the US: flatiron health SEER and NPCR.2020. Accessed February 2023.https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.16.20037143v2","DOI":"10.1101\/2020.03.16.20037143"},{"key":"e_1_2_13_12_1","unstructured":"BirnbaumB NussbaumN Seidl\u2010RathkopfK et al.Model\u2010assisted cohort selection with bias analysis for generating large\u2010scale cohorts from the EHR for oncology research.2020. Accessed February 2023.https:\/\/arxiv.org\/abs\/2001.09765"},{"key":"e_1_2_13_13_1","first-page":"LB2601","article-title":"A randomized, double\u2010blind, placebo\u2010controlled study of venetoclax with azacitidine vs azacitidine in treatment\u2010na\u00efve patients with acute myeloid leukemia ineligible for intensive therapy\u2010VIALE\u2010A","author":"DiNardo C","year":"2020","journal-title":"EHA Library"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.5124\/jkma.2011.54.10.1006"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.083"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6430","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.6430","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:04:51Z","timestamp":1786968291000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":15,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/cam4.6430"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6430","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"2023-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}